GBA Presents: THE GREEN MARKET

WRONG-WAY-CATHIE-- DOCCUSIGN

  • When shares plunged, Ark Invest added significantly.
  • Last week, ARKK started liquidating its position.
  • Shares could hit a new low with further market weakness.
 
In the end, the Ark Invest team has completely changed course when it comes to DocuSign. A month ago, all three active ETFs that held the stock bought the dip, but last week ARKK sold a significant amount of its position. Given how much most to all of the Cathie Wood names are off their highs, it's very notable to see the firm's flagship fund essentially liquidate this holding

THUS THE LARGE INSIDER BUY TO TRY AND HALT THE FALL! VAN DID YOU CHECK ON THAT DID THEY BUY @ MARKET PRICE?
 
Savant moments just happen and this is one of those.....

....Ebay has lived at this level forever. And I know Stoney here has agreed with me...

But here's the thing....
Buy this stock.
You ask me why.
Because I said to.

Ebay is heading for $80 plus.
$100 plus.
And I have no position fwiw.
But it is.
Buy this stock!
As a granny pick.
The time has come.
November Foxtrot Tango.
GME is a wannabe.
 
GBA GREEN IDEA--->

MY FAVORITE-> Organigram upgraded to Speculative Buy from Hold at Canaccord 07:25 OGI Canaccord analyst Matt Bottomley upgraded Organigram to Speculative Buy from Hold with a price target of C$3.25, up from C$3.00. The company's fiscal Q1 financial results represented a second sequential quarter of revenues and adjusted EBITDA that came in higher than expectations, Bottomley tells investors in a research note. The analyst believes Organigram continues to build on the positive momentum from the end of 2021. The company has "demonstrated strong execution" over the past two quarters in its ability to pivot products and has effectively doubled its market share on a year-over-year basis, says Bottomley.

OGI-$
 
Van do you want me to contact Barclays? They are killing you today.Not fair.

:mad:ZoomInfo price target lowered to $68 from $86 at Barclays 07:10 ZI Barclays analyst Raimo…
 
Ginkgo Bioworks sees 2021 revenue above guidance 07:08 DNA Ginkgo Bioworks announced preliminary 2021 performance updates. Ginkgo expects to meet or exceed its key 2021 targets for the commencement of new cell programs and revenue from its cell programming and biosecurity offerings. Preliminary unaudited Foundry revenue is expected to exceed previously disclosed outlook of $100M for full year 2021, inclusive of both downstream value share and services revenue. Preliminary unaudited Biosecurity revenue is expected to exceed previous outlook of $110M for full year 2021 by over 50%. "In our Q3 earnings call Ginkgo updated our 2021 outlook on the number of new cell programs, Foundry revenue, and Biosecurity revenue - I'm happy to report that based on preliminary unaudited estimates for the full year, we expect to meet or beat all of those, with Biosecurity revenue exceeding our outlook by over 50%," said CEO Jason Kelly. "Scale is fundamental to our strategy and competitive advantage, and with over $1.6B in gross proceeds from our public debut, we believe we are well-positioned to continue to play offense in the coming years. The past year was transformational for Ginkgo, and I am grateful for the dedication of our team and the commitment of our partners in contributing to our success in 2021."
 
What The Hell crawled up Raimo's ass this morning!

Jamf Holding price target lowered to $37 from $46 at Barclays 07:06 JAMF Barclays analyst Raimo Lenschow lowered the firm's price target on Jamf Holding to $37 from $46 and keeps an Equal Weight rating on the shares. The analyst says the main question for software investors in 2022 is not around end demand ,as there are "no issues there," but the correct valuation level for the space. "Are we going back to the long term average, or should software bounce back to the more recent highs given the exciting structural growth profile? We are in the former camp," Lenschow tells investors in a research note.
 
You must log in or register to reply here.
Back
Top